INVO Fertility, Inc.
No enriched coverage for $IVF in the last 7 days.
No SEC Form 4 filings for $IVF in the last 30 days.
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “ Agreement ”), dated as of July 24, 2026 (the “ Execution Date ”), by and between INVO Fertility, Inc. , a Nevada corporation (the “ Company ”), and Alumni Capital LP
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001417926 0001417926 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure 23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabiliti
Recent IVF coverage spans financial news, corporate actions and earnings.
The filing discloses a new equity purchase agreement that can increase near-term dilution over time, depending on drawdowns and pricing mechanics.
Deal closes and adds a new clinic to consolidated results; near-term impact hinges on transition/support costs and free-cash-flow funding mechanics.
The filing combines an operating improvement (revenue up, net loss narrowed) with a capital-structure de-risking (preferred stock and warrant liabilities removed), which can change near-term valuation and financing risk.
INVO Fertility faces a Nasdaq compliance issue stemming from delayed financial filings, indicating potential financial instability and operational risks.
The late filing of INVO Fertility's 10-K indicates potential internal control issues and may raise concerns among investors.
alphai scores every news story that mentions IVF with an AI model for sentiment and relevance, and aggregates insider trades from INVO Fertility, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “ Agreement ”), dated as of July 24, 2026 (the “ Execution Date ”), by and between INVO Fertility, Inc. , a Nevada corporation (the “ Company ”), and Alumni Capital LP
6 min readINVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001417926 0001417926 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
4 min readINVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure 23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabiliti
6 min readINVO Fertility Inc (IVF) has been notified by Nasdaq's Listing Qualifications Department regarding a compliance issue due to its failure to submit its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. This delay is attributed to complex accounting matters, leading to a low GF Score™ of 29/100, indicating significant financial and profitability challenges. The company, which operates in the medical devices and instruments industry with its INVOcell device, has a market capitalization of $3.1 million and is currently not generating profits, signaling caution for investors.
3 min readINVO Fertility (IVF) has received a notice from Nasdaq regarding its non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The delay is attributed to complex accounting matters, including tax provision, warrant, and variable interest entity accounting. Nasdaq's notice does not immediately impact the company's stock listing.
2 min readINVO Fertility (IVF) has signed two financial agreements to enhance its liquidity. An institutional investor will exercise existing warrants for approximately $7.5 million, receiving new unregistered warrants. Additionally, the company has engaged Maxim Group as its exclusive lead warrant solicitation agent.
2 min readSARASOTA, Fla., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- INVO Fertility, Inc. ( "INVO" ) ( NASDAQ: IVF ) , a healthcare company focused on the fertility market, announced today that it will effect a 1-for-8 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 ...
2 min readSARASOTA, Fla., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- INVO Fertility, Inc. ( Nasdaq: IVF ) ( "INVO Fertility" or the "Company" ) , a healthcare fertility company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced ...
3 min readINVO Fertility Inc ( NASDAQ:IVF ) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.
3 min readSARASOTA, Fla., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- INVO Fertility, Inc. ( Nasdaq: IVF ) ( "INVO Fertility" or the "Company" ) , a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related ...
3 min read
